New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
08:13 EDTAMRNAmarin to present data showing Vascepa significantly reduced ApoC-III levels
Amarin announced the presentation at the National Lipid Association Annual Scientific Sessions, of new post-hoc analyses of the MARINE and ANCHOR studies that showed the use of Vascepa capsules significantly reduced apolipoprotein C-III, or ApoC-III, levels. ApoC-III is a small protein that resides on various lipoproteins, and is an important regulator of lipoprotein and triglyceride metabolism. Steven B. Ketchum, Ph.D., president of research and development, senior vice president, Amarin stated, "The significantly reduced Apo C-III levels with Vascepa in the MARINE and ANCHOR trials add to previously reported TG- and ApoB-lowering effects in patients from these studies. We are pleased to continue to analyze and share data from these trials that support the clinical value of Vascepa as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia."
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
15:00 EDTAMRNStonepine Capital reports 5.2% passive stake in Amarin
November 17, 2014
09:06 EDTAMRNAmarin reports new data from MARINE, ANCHOR phase 3 studies
Amarin announced the presentation of new data and related analyses from the MARINE and ANCHOR phase 3 studies. The data show that use of Vascepa capsules significantly reduced remnant-like particle cholesterol, or RLP-C, levels -- a cardiovascular risk factor -- including significant placebo-adjusted reductions in RLP-C in studied patient populations with triglyceride, or TG, levels greater than or equal to 200 mg/dL and greater than or equal to 500 mg/dL, including patients that received statin therapy. The data were presented today by Dr. Christie M. Ballantyne as part of a moderated poster session at the American Heart Association Scientific Sessions in Chicago. Remnant-like particle cholesterol is an important emerging risk factor for cardiovascular disease and represents the cholesterol content of a subset of triglyceride-rich lipoproteins, or TRL, called remnants. In the fasting state this subset of TRLs is comprised of very low-density lipoproteins, or VLDL, and intermediate-density lipoproteins, or IDL, and in the non-fasting state includes these two types of lipoproteins together with chylomicron remnants.Elevated plasma TG levels are a marker of elevated remnant cholesterol and are associated with increased risk for cardiovascular disease.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use